Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Article summary

Equillium, Inc. has initiated its Phase 1 clinical trial for EQ504, an investigational oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator, by dosing the first subject in Australia.